A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy

INTRODUCTION: Protein deimination, defined as the post-translational conversion of protein-bound arginine to citrulline, is carried out by a family of 5 calcium-dependent enzymes, the peptidylarginine deiminases (PADs) and has been linked to various cancers. Cellular microvesicle (MV) release, whic...

Full description

Bibliographic Details
Main Authors: Kholia, Sharadkumar Rajnikant, Jorfi, Samireh, Thompson, Paul R., Causey, Corey P., Nicholas, Anthony P., Inal, Jameel, Lange, Sigrun
Format: Article
Language:English
Published: Co-Action Publishing 2015
Subjects:
Online Access:https://repository.londonmet.ac.uk/1001/1/JEV%20PAD%20paper%202015.pdf
_version_ 1804071595276238848
author Kholia, Sharadkumar Rajnikant
Jorfi, Samireh
Thompson, Paul R.
Causey, Corey P.
Nicholas, Anthony P.
Inal, Jameel
Lange, Sigrun
author_facet Kholia, Sharadkumar Rajnikant
Jorfi, Samireh
Thompson, Paul R.
Causey, Corey P.
Nicholas, Anthony P.
Inal, Jameel
Lange, Sigrun
author_sort Kholia, Sharadkumar Rajnikant
collection LMU
description INTRODUCTION: Protein deimination, defined as the post-translational conversion of protein-bound arginine to citrulline, is carried out by a family of 5 calcium-dependent enzymes, the peptidylarginine deiminases (PADs) and has been linked to various cancers. Cellular microvesicle (MV) release, which is involved in cancer progression, and deimination have not been associated before. We hypothesize that elevated PAD expression, observed in cancers, causes increased MV release in cancer cells and contributes to cancer progression. BACKGROUND: We have previously reported that inhibition of MV release sensitizes cancer cells to chemotherapeutic drugs. PAD2 and PAD4, the isozymes expressed in patients with malignant tumours, can be inhibited with the pan-PAD-inhibitor chloramidine (Cl-am). We sought to investigate whether Cl-am can inhibit MV release and whether this pathway could be utilized to further increase the sensitivity of cancer cells to drug-directed treatment. METHODS: Prostate cancer cells (PC3) were induced to release high levels of MVs upon BzATP stimulation of P2X7 receptors. Western blotting with the pan-protein deimination antibody F95 was used to detect a range of deiminated proteins in cells stimulated to microvesiculate. Changes in deiminated proteins during microvesiculation were revealed by immunoprecipitation and immunoblotting, and mass spectrometry identified deiminated target proteins with putative roles in microvesiculation. CONCLUSION: We report for the first time a novel function of PADs in the biogenesis of MVs in cancer cells. Our results reveal that during the stimulation of prostate cancer cells (PC3) to microvesiculate, PAD2 and PAD4 expression levels and the deimination of cytoskeletal actin are increased. Pharmacological inhibition of PAD enzyme activity using Cl-am significantly reduced MV release and abrogated the deimination of cytoskeletal actin. We demonstrated that combined Cl-am and methotrexate (MTX) treatment of prostate cancer cells increased the cytotoxic effect of MTX synergistically. Refined PAD inhibitors may form part of a novel combination therapy in cancer treatment.
first_indexed 2024-07-09T03:45:45Z
format Article
id oai:repository.londonmet.ac.uk:1001
institution London Metropolitan University
language English
last_indexed 2024-07-09T03:45:45Z
publishDate 2015
publisher Co-Action Publishing
record_format eprints
spelling oai:repository.londonmet.ac.uk:10012020-03-18T11:13:28Z http://repository.londonmet.ac.uk/1001/ A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy Kholia, Sharadkumar Rajnikant Jorfi, Samireh Thompson, Paul R. Causey, Corey P. Nicholas, Anthony P. Inal, Jameel Lange, Sigrun 610 Medicine & health INTRODUCTION: Protein deimination, defined as the post-translational conversion of protein-bound arginine to citrulline, is carried out by a family of 5 calcium-dependent enzymes, the peptidylarginine deiminases (PADs) and has been linked to various cancers. Cellular microvesicle (MV) release, which is involved in cancer progression, and deimination have not been associated before. We hypothesize that elevated PAD expression, observed in cancers, causes increased MV release in cancer cells and contributes to cancer progression. BACKGROUND: We have previously reported that inhibition of MV release sensitizes cancer cells to chemotherapeutic drugs. PAD2 and PAD4, the isozymes expressed in patients with malignant tumours, can be inhibited with the pan-PAD-inhibitor chloramidine (Cl-am). We sought to investigate whether Cl-am can inhibit MV release and whether this pathway could be utilized to further increase the sensitivity of cancer cells to drug-directed treatment. METHODS: Prostate cancer cells (PC3) were induced to release high levels of MVs upon BzATP stimulation of P2X7 receptors. Western blotting with the pan-protein deimination antibody F95 was used to detect a range of deiminated proteins in cells stimulated to microvesiculate. Changes in deiminated proteins during microvesiculation were revealed by immunoprecipitation and immunoblotting, and mass spectrometry identified deiminated target proteins with putative roles in microvesiculation. CONCLUSION: We report for the first time a novel function of PADs in the biogenesis of MVs in cancer cells. Our results reveal that during the stimulation of prostate cancer cells (PC3) to microvesiculate, PAD2 and PAD4 expression levels and the deimination of cytoskeletal actin are increased. Pharmacological inhibition of PAD enzyme activity using Cl-am significantly reduced MV release and abrogated the deimination of cytoskeletal actin. We demonstrated that combined Cl-am and methotrexate (MTX) treatment of prostate cancer cells increased the cytotoxic effect of MTX synergistically. Refined PAD inhibitors may form part of a novel combination therapy in cancer treatment. Co-Action Publishing 2015-06-22 Article PeerReviewed text en https://repository.londonmet.ac.uk/1001/1/JEV%20PAD%20paper%202015.pdf Kholia, Sharadkumar Rajnikant, Jorfi, Samireh, Thompson, Paul R., Causey, Corey P., Nicholas, Anthony P., Inal, Jameel and Lange, Sigrun (2015) A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy. Journal of Extracellular Vesicles, 4 (26192). ISSN 2001-3078 http://www.journalofextracellularvesicles.net/index.php/jev/article/view/26192 10.3402/jev.v4.26192
spellingShingle 610 Medicine & health
Kholia, Sharadkumar Rajnikant
Jorfi, Samireh
Thompson, Paul R.
Causey, Corey P.
Nicholas, Anthony P.
Inal, Jameel
Lange, Sigrun
A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy
title A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy
title_full A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy
title_fullStr A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy
title_full_unstemmed A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy
title_short A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy
title_sort novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of pad inhibition in sensitizing prostate cancer cells to chemotherapy
topic 610 Medicine & health
url https://repository.londonmet.ac.uk/1001/1/JEV%20PAD%20paper%202015.pdf
work_keys_str_mv AT kholiasharadkumarrajnikant anovelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT jorfisamireh anovelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT thompsonpaulr anovelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT causeycoreyp anovelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT nicholasanthonyp anovelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT inaljameel anovelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT langesigrun anovelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT kholiasharadkumarrajnikant novelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT jorfisamireh novelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT thompsonpaulr novelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT causeycoreyp novelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT nicholasanthonyp novelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT inaljameel novelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy
AT langesigrun novelroleforpeptidylargininedeiminasesinmicrovesiclereleaserevealstherapeuticpotentialofpadinhibitioninsensitizingprostatecancercellstochemotherapy